Independently of KEAP1/NRF2/CUL3 mutations, altered protein-protein interactions and KEAP1-inactivating posttranslational modifications also activate NRF2 in cancer, most notably in tissues of the liver, breast and kidney [9]. Here, CUL3 is linked to cancer.